Bausch + Lomb buys US rights to Stada's Lucentis biosimilar

Bausch + Lomb has bought US and Canadian rights to a potential biosimilar competitor to Novartis’ Lucentis from Germany’s Stada, as the blockbuster approaches the end of its patent protecte

UK court imposes safety rules on off-label use of Avastin in...

Bayer has said a new UK court ruling could limit off-label use of Roche's Avastin in ophthalmology by imposing stricter safety and consent measures.

First patient dosed in trial of Allergan/Editas’ CRISPR blin...

Novartis' Beovu safety woes could cost billions of dollars, ...

The launch of Novartis’ Beovu ophthalmology drug could be compromised after a safety warning from doctors over several cases of sight-threatening inflammation of blood vessels.

More pressure on Bayer as EU approves Novartis' Beovu in wet...

The market for ophthalmology drugs in Europe just got hotter with the approval of Novartis’ Beovu for neovascular or “wet” age-related macular degeneration, offering a less frequent dosing

Verily plans digital ophthalmology joint venture with Santen

Verily is planning a digital ophthalmology joint venture with Japan’s specialist in the field, Santen.